Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Biosergen
Its shares trade on Nasdaq Stockholm under the ticker BIOSGN.ST. It has been listed since 24 June 2021. In the fiscal year to 31 December 2021, it reported revenue of SEK 8.6m and a net loss of SEK 34.6m. At that date it held total assets of SEK 29.5m and shareholders' equity of SEK 20.2m.
Biosergen AB operates as a biopharmaceutical company. The company is headquartered in Solna, Stockholm. The company went IPO on 2021-06-24. The company carries out biopharmaceutical research and development through its Subsidiary Biosergen AS from laboratory facilities in Trondheim, Norway and several other places worldwide. The firm is developing BSG005, a potentially disruptive antifungal drug which has demonstrated safety and potency advantages over competing antifungals. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS, cancer and transplant patients every year. At equal dose levels BSG005 has demonstrated a three-to-fouold potency advantage against the relevant fungal strains compared to the current standard of care, while being completely free of the kidney toxicity hampering other drugs in its class.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Jun 2021
- Website
- biosergen.net ↗
Leadership
Pay as last reported
- Peder Møller Andersen, MDChief Executive Officer
- Torsten Rüdiger Goesch, MD, PhDChairman, since 2015
- Niels Laursen, MBAChief Financial Officer
- Richard Forster, PhDChief Technology Officer
- Mattias Klintemar, MBADirector, since 2021
- Lena Birgitta Degling Wikingsson, PhDIndependent Director, since 2021
- Achim Kaufhold, MD, PhDIndependent Director, since 2021
- Marianne Kock, EMBAIndependent Director, since 2021
- Hanne Mette Dyrlie Kristensen, MBAIndependent Director, since 2021
- Henrik Kristian MoltkeIndependent Director, since 2021
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Biosergen AB develops BSG005 with three-to-fourfold potency advantage over current antifungals.
- Biosergen AS conducts R&D in Trondheim, Norway, and other global locations.
- BSG005 shows safety and potency advantages without kidney toxicity.
Weaknesses
- Biosergen AB's IPO occurred on 24 June 2021, a relatively recent listing.
- The company focuses on invasive fungal infections affecting immune-compromised patients.
- Biosergen AB operates from Solna, Stockholm, Sweden, with limited global presence.
Opportunities
- Biosergen AB targets the market for invasive fungal infections in AIDS, cancer, and transplant patients.
- The global market for antifungal drugs is large, with hundreds of thousands of annual deaths.
- BSG005's safety profile could expand its use beyond current antifungal treatments.
Threats
- Biosergen AB faces competition from existing antifungal drugs in its class.
- The company's reliance on BSG005 for its primary product could pose risks.
- Regulatory approval processes for new antifungals may delay market entry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.